PTU-014 Safety and efficacy of endoscopic resection followed by radiofrequency ablation for Barrett's high-grade dysplasia and intramucosal cancer

IntroductionEndoscopic resection (ER) is a minimally invasive treatment for Barrett's high-grade dysplasia (HGD) and intramucosal cancer (IMC). However, a significant proportion of patients may develop malignant transformation of remaining Barrett's. Radiofrequency ablation (RFA) is a new,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2010-04, Vol.59 (Suppl 1), p.A54-A54
Hauptverfasser: Mannath, J, Ragunath, K, Rembacken, B J, Pouw, R E, Sondermeijer, C M, Bergman, J J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A54
container_issue Suppl 1
container_start_page A54
container_title Gut
container_volume 59
creator Mannath, J
Ragunath, K
Rembacken, B J
Pouw, R E
Sondermeijer, C M
Bergman, J J
description IntroductionEndoscopic resection (ER) is a minimally invasive treatment for Barrett's high-grade dysplasia (HGD) and intramucosal cancer (IMC). However, a significant proportion of patients may develop malignant transformation of remaining Barrett's. Radiofrequency ablation (RFA) is a new, safe and effective modality for eradicating dysplasia and intestinal metaplasia. However there are limited data on the safety and efficacy of a combined approach including ER followed by RFA.MethodsThe aim was to assess the feasibility, safety and efficacy of the combined approach. Patients were enrolled from two tertiary referral centres in UK, as part of a multicentre European trial (EURO II). All visible mucosal lesions were removed by ER. RFA was carried out at 6–8 weekly intervals for a maximum of five sessions. HALO 360 were used for circumferential ablation followed by HALO 90 for any remaining islands.Results20 patients (average age 63, 19 males) with a mean Barrett's length of 4.8 cm (range 2–11 cm) underwent ER of visible mucosal lesions. All patients had Paris 0-II lesions (IIa-14, IIb-5 and IIc-1) with a mean size of 12 mm (range 4–20 mm). ER was carried out using multiband mucosectomy device in 19 patients and ER cap in one patient. En-bloc resection was achieved in eight cases, the rest requiring a piecemeal approach. 10 (50%) patients were up-staged from HGD to IMC following ER. RFA was carried out at least 6 weeks after ER. After a median follow-up of 11 months (IQR 7.5–16.5) and a mean of 2.2 (range 1–5) RFA sessions, none of the patients had residual or recurrent dysplasia. On average, the combined approach resulted in 90% reduction in the endoscopically-observed extent of Barrett's mucosa. In eight patients who had completed the treatment regimen, complete histological resolution of intestinal metaplasia was achieved. Three patients (15%) developed minor procedure-related complications including 1 food bolus obstruction which was managed endoscopically, 1 superficial mucosal tear and 1 episode of self-limiting chest pain.ConclusionEndoscopic resection followed by radiofrequency ablation is a feasible, safe and effective approach for eradicating dysplasia and intestinal metaplasia in Barrett's oesophagus. Long-term follow-up is warranted before this treatment modality could be implemented in routine clinical practice.
doi_str_mv 10.1136/gut.2009.209015z
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2043348389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2043348389</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1059-c27792b8706123ba150d66651ef523e236dcbd52f7372b249077d9997b98516c3</originalsourceid><addsrcrecordid>eNqFkLtOwzAUhi0EEqWwM1piYEApx3YS2yNU3KRKIAFz5GtJlcbFToXCxMIb8IQ8CYF2Zzln-f7zH30IHROYEMLK8_m6m1AAOQwJpHjfQSOSlyJjVIhdNAIgPCt4LvfRQUoLABBCkhH6enh6zoDk3x-fj8q7rseqtdh5Xxtlehw8dq0NyYRVbXB0yZmuDi32oWnCm7NY9zgqWwcf3evatUNE6UZtmYgvVYyu604TfqnnL9l8YB22fVo1KtXqr6tuu6iWaxOSarBRrXHxEO151SR3tN1j9Hx99TS9zWb3N3fTi1mmCRQyM5RzSbXgUBLKtCIF2LIsC-J8QZmjrLRG24J6zjjVNJfAuZVSci1FQUrDxuhkc3cVw_B96qpFWMd2qKwo5Izlggk5ULChTAwpReerVayXKvYVgerXfTW4r37dV1v3Q-RsE9HLxf_0D2j2h3c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2043348389</pqid></control><display><type>article</type><title>PTU-014 Safety and efficacy of endoscopic resection followed by radiofrequency ablation for Barrett's high-grade dysplasia and intramucosal cancer</title><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Mannath, J ; Ragunath, K ; Rembacken, B J ; Pouw, R E ; Sondermeijer, C M ; Bergman, J J</creator><creatorcontrib>Mannath, J ; Ragunath, K ; Rembacken, B J ; Pouw, R E ; Sondermeijer, C M ; Bergman, J J</creatorcontrib><description>IntroductionEndoscopic resection (ER) is a minimally invasive treatment for Barrett's high-grade dysplasia (HGD) and intramucosal cancer (IMC). However, a significant proportion of patients may develop malignant transformation of remaining Barrett's. Radiofrequency ablation (RFA) is a new, safe and effective modality for eradicating dysplasia and intestinal metaplasia. However there are limited data on the safety and efficacy of a combined approach including ER followed by RFA.MethodsThe aim was to assess the feasibility, safety and efficacy of the combined approach. Patients were enrolled from two tertiary referral centres in UK, as part of a multicentre European trial (EURO II). All visible mucosal lesions were removed by ER. RFA was carried out at 6–8 weekly intervals for a maximum of five sessions. HALO 360 were used for circumferential ablation followed by HALO 90 for any remaining islands.Results20 patients (average age 63, 19 males) with a mean Barrett's length of 4.8 cm (range 2–11 cm) underwent ER of visible mucosal lesions. All patients had Paris 0-II lesions (IIa-14, IIb-5 and IIc-1) with a mean size of 12 mm (range 4–20 mm). ER was carried out using multiband mucosectomy device in 19 patients and ER cap in one patient. En-bloc resection was achieved in eight cases, the rest requiring a piecemeal approach. 10 (50%) patients were up-staged from HGD to IMC following ER. RFA was carried out at least 6 weeks after ER. After a median follow-up of 11 months (IQR 7.5–16.5) and a mean of 2.2 (range 1–5) RFA sessions, none of the patients had residual or recurrent dysplasia. On average, the combined approach resulted in 90% reduction in the endoscopically-observed extent of Barrett's mucosa. In eight patients who had completed the treatment regimen, complete histological resolution of intestinal metaplasia was achieved. Three patients (15%) developed minor procedure-related complications including 1 food bolus obstruction which was managed endoscopically, 1 superficial mucosal tear and 1 episode of self-limiting chest pain.ConclusionEndoscopic resection followed by radiofrequency ablation is a feasible, safe and effective approach for eradicating dysplasia and intestinal metaplasia in Barrett's oesophagus. Long-term follow-up is warranted before this treatment modality could be implemented in routine clinical practice.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gut.2009.209015z</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Barrett's esophagus ; Cancer ; Dysplasia ; Endoscopy ; Intestine ; Metaplasia ; Mucosa ; Pain ; Patients ; Radiofrequency ablation ; Safety</subject><ispartof>Gut, 2010-04, Vol.59 (Suppl 1), p.A54-A54</ispartof><rights>2010, Published by the BMJ Publishing Group Limited For permission to use, (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2010 © 2010, Published by the BMJ Publishing Group Limited For permission to use, (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://gut.bmj.com/content/59/Suppl_1/A54.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://gut.bmj.com/content/59/Suppl_1/A54.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids></links><search><creatorcontrib>Mannath, J</creatorcontrib><creatorcontrib>Ragunath, K</creatorcontrib><creatorcontrib>Rembacken, B J</creatorcontrib><creatorcontrib>Pouw, R E</creatorcontrib><creatorcontrib>Sondermeijer, C M</creatorcontrib><creatorcontrib>Bergman, J J</creatorcontrib><title>PTU-014 Safety and efficacy of endoscopic resection followed by radiofrequency ablation for Barrett's high-grade dysplasia and intramucosal cancer</title><title>Gut</title><description>IntroductionEndoscopic resection (ER) is a minimally invasive treatment for Barrett's high-grade dysplasia (HGD) and intramucosal cancer (IMC). However, a significant proportion of patients may develop malignant transformation of remaining Barrett's. Radiofrequency ablation (RFA) is a new, safe and effective modality for eradicating dysplasia and intestinal metaplasia. However there are limited data on the safety and efficacy of a combined approach including ER followed by RFA.MethodsThe aim was to assess the feasibility, safety and efficacy of the combined approach. Patients were enrolled from two tertiary referral centres in UK, as part of a multicentre European trial (EURO II). All visible mucosal lesions were removed by ER. RFA was carried out at 6–8 weekly intervals for a maximum of five sessions. HALO 360 were used for circumferential ablation followed by HALO 90 for any remaining islands.Results20 patients (average age 63, 19 males) with a mean Barrett's length of 4.8 cm (range 2–11 cm) underwent ER of visible mucosal lesions. All patients had Paris 0-II lesions (IIa-14, IIb-5 and IIc-1) with a mean size of 12 mm (range 4–20 mm). ER was carried out using multiband mucosectomy device in 19 patients and ER cap in one patient. En-bloc resection was achieved in eight cases, the rest requiring a piecemeal approach. 10 (50%) patients were up-staged from HGD to IMC following ER. RFA was carried out at least 6 weeks after ER. After a median follow-up of 11 months (IQR 7.5–16.5) and a mean of 2.2 (range 1–5) RFA sessions, none of the patients had residual or recurrent dysplasia. On average, the combined approach resulted in 90% reduction in the endoscopically-observed extent of Barrett's mucosa. In eight patients who had completed the treatment regimen, complete histological resolution of intestinal metaplasia was achieved. Three patients (15%) developed minor procedure-related complications including 1 food bolus obstruction which was managed endoscopically, 1 superficial mucosal tear and 1 episode of self-limiting chest pain.ConclusionEndoscopic resection followed by radiofrequency ablation is a feasible, safe and effective approach for eradicating dysplasia and intestinal metaplasia in Barrett's oesophagus. Long-term follow-up is warranted before this treatment modality could be implemented in routine clinical practice.</description><subject>Barrett's esophagus</subject><subject>Cancer</subject><subject>Dysplasia</subject><subject>Endoscopy</subject><subject>Intestine</subject><subject>Metaplasia</subject><subject>Mucosa</subject><subject>Pain</subject><subject>Patients</subject><subject>Radiofrequency ablation</subject><subject>Safety</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqFkLtOwzAUhi0EEqWwM1piYEApx3YS2yNU3KRKIAFz5GtJlcbFToXCxMIb8IQ8CYF2Zzln-f7zH30IHROYEMLK8_m6m1AAOQwJpHjfQSOSlyJjVIhdNAIgPCt4LvfRQUoLABBCkhH6enh6zoDk3x-fj8q7rseqtdh5Xxtlehw8dq0NyYRVbXB0yZmuDi32oWnCm7NY9zgqWwcf3evatUNE6UZtmYgvVYyu604TfqnnL9l8YB22fVo1KtXqr6tuu6iWaxOSarBRrXHxEO151SR3tN1j9Hx99TS9zWb3N3fTi1mmCRQyM5RzSbXgUBLKtCIF2LIsC-J8QZmjrLRG24J6zjjVNJfAuZVSci1FQUrDxuhkc3cVw_B96qpFWMd2qKwo5Izlggk5ULChTAwpReerVayXKvYVgerXfTW4r37dV1v3Q-RsE9HLxf_0D2j2h3c</recordid><startdate>201004</startdate><enddate>201004</enddate><creator>Mannath, J</creator><creator>Ragunath, K</creator><creator>Rembacken, B J</creator><creator>Pouw, R E</creator><creator>Sondermeijer, C M</creator><creator>Bergman, J J</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201004</creationdate><title>PTU-014 Safety and efficacy of endoscopic resection followed by radiofrequency ablation for Barrett's high-grade dysplasia and intramucosal cancer</title><author>Mannath, J ; Ragunath, K ; Rembacken, B J ; Pouw, R E ; Sondermeijer, C M ; Bergman, J J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1059-c27792b8706123ba150d66651ef523e236dcbd52f7372b249077d9997b98516c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Barrett's esophagus</topic><topic>Cancer</topic><topic>Dysplasia</topic><topic>Endoscopy</topic><topic>Intestine</topic><topic>Metaplasia</topic><topic>Mucosa</topic><topic>Pain</topic><topic>Patients</topic><topic>Radiofrequency ablation</topic><topic>Safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mannath, J</creatorcontrib><creatorcontrib>Ragunath, K</creatorcontrib><creatorcontrib>Rembacken, B J</creatorcontrib><creatorcontrib>Pouw, R E</creatorcontrib><creatorcontrib>Sondermeijer, C M</creatorcontrib><creatorcontrib>Bergman, J J</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mannath, J</au><au>Ragunath, K</au><au>Rembacken, B J</au><au>Pouw, R E</au><au>Sondermeijer, C M</au><au>Bergman, J J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PTU-014 Safety and efficacy of endoscopic resection followed by radiofrequency ablation for Barrett's high-grade dysplasia and intramucosal cancer</atitle><jtitle>Gut</jtitle><date>2010-04</date><risdate>2010</risdate><volume>59</volume><issue>Suppl 1</issue><spage>A54</spage><epage>A54</epage><pages>A54-A54</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><abstract>IntroductionEndoscopic resection (ER) is a minimally invasive treatment for Barrett's high-grade dysplasia (HGD) and intramucosal cancer (IMC). However, a significant proportion of patients may develop malignant transformation of remaining Barrett's. Radiofrequency ablation (RFA) is a new, safe and effective modality for eradicating dysplasia and intestinal metaplasia. However there are limited data on the safety and efficacy of a combined approach including ER followed by RFA.MethodsThe aim was to assess the feasibility, safety and efficacy of the combined approach. Patients were enrolled from two tertiary referral centres in UK, as part of a multicentre European trial (EURO II). All visible mucosal lesions were removed by ER. RFA was carried out at 6–8 weekly intervals for a maximum of five sessions. HALO 360 were used for circumferential ablation followed by HALO 90 for any remaining islands.Results20 patients (average age 63, 19 males) with a mean Barrett's length of 4.8 cm (range 2–11 cm) underwent ER of visible mucosal lesions. All patients had Paris 0-II lesions (IIa-14, IIb-5 and IIc-1) with a mean size of 12 mm (range 4–20 mm). ER was carried out using multiband mucosectomy device in 19 patients and ER cap in one patient. En-bloc resection was achieved in eight cases, the rest requiring a piecemeal approach. 10 (50%) patients were up-staged from HGD to IMC following ER. RFA was carried out at least 6 weeks after ER. After a median follow-up of 11 months (IQR 7.5–16.5) and a mean of 2.2 (range 1–5) RFA sessions, none of the patients had residual or recurrent dysplasia. On average, the combined approach resulted in 90% reduction in the endoscopically-observed extent of Barrett's mucosa. In eight patients who had completed the treatment regimen, complete histological resolution of intestinal metaplasia was achieved. Three patients (15%) developed minor procedure-related complications including 1 food bolus obstruction which was managed endoscopically, 1 superficial mucosal tear and 1 episode of self-limiting chest pain.ConclusionEndoscopic resection followed by radiofrequency ablation is a feasible, safe and effective approach for eradicating dysplasia and intestinal metaplasia in Barrett's oesophagus. Long-term follow-up is warranted before this treatment modality could be implemented in routine clinical practice.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/gut.2009.209015z</doi></addata></record>
fulltext fulltext
identifier ISSN: 0017-5749
ispartof Gut, 2010-04, Vol.59 (Suppl 1), p.A54-A54
issn 0017-5749
1468-3288
language eng
recordid cdi_proquest_journals_2043348389
source BMJ Journals - NESLi2; PubMed Central
subjects Barrett's esophagus
Cancer
Dysplasia
Endoscopy
Intestine
Metaplasia
Mucosa
Pain
Patients
Radiofrequency ablation
Safety
title PTU-014 Safety and efficacy of endoscopic resection followed by radiofrequency ablation for Barrett's high-grade dysplasia and intramucosal cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A13%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PTU-014%E2%80%85Safety%20and%20efficacy%20of%20endoscopic%20resection%20followed%20by%20radiofrequency%20ablation%20for%20Barrett's%20high-grade%20dysplasia%20and%20intramucosal%20cancer&rft.jtitle=Gut&rft.au=Mannath,%20J&rft.date=2010-04&rft.volume=59&rft.issue=Suppl%201&rft.spage=A54&rft.epage=A54&rft.pages=A54-A54&rft.issn=0017-5749&rft.eissn=1468-3288&rft_id=info:doi/10.1136/gut.2009.209015z&rft_dat=%3Cproquest_cross%3E2043348389%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2043348389&rft_id=info:pmid/&rfr_iscdi=true